Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months
Authors' conclusion
We conclude that long-term use of tirzepatide in OW/OB adults with T1D results in more than 23% weight loss and sustained improvement in glucose control. Irrespective of changes in weight and/or HbA1c, we observed significant improvement in cardiovascular biomarkers and preservation of kidney function.
Study context
- Population
- Overweight/obese adults with T1D
- Participants
- 84 vs 38
- Exposure
- Tirzepatide vs controls
- Tirzepatiden = 84
- Controlsn = 38reference
- Outcome
- Changes in lipids, blood pressure and eGFR over time (cardiovascular disease (CVD) and diabetic kidney disease (DKD) biomarkers)
- Follow-up
- 21 months
Methodological detailsretrospective chart review, frequency-matched controls, off-label use, Linear mixed effects models
- Retrospective chart review
- Frequency-matched controls
- Off-label use
- Linear mixed effects models
Main finding
As reported in the abstract
- Tirzepatide users significantly improved total and LDL cholesterol, TG, systolic blood pressure and estimated glomerular filtration rate (eGFR); changes remained significant after adjusting for weight and HbA1c
- eGFR declined significantly in controls but not in tirzepatide users
Observational data: associations, not effects.
Further findings
Baseline BMI
P = 0.03
| Outcome | Tirzepatide | Controls | P value |
|---|---|---|---|
| Weight change · 21 months | −59 ± 4.6 lbs | +1.7 ± 5.0 lbs | |
| Percent change | −23.4% | +1.8% | |
| HbA1c change · 21 monthsGreater decrease with Tirzepatide | −0.50 ± 0.07 % | −0.24 ± 0.09 % | P = 0.017 |
Original publication
Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months. Diabetes Technol Ther. Published 1 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →